Real-world Data Shows Teclistamab Can Benefit Many Multiple Myeloma Patients Who Would Have Been Ineligible for Pivotal Trial
Retrospective study revealed efficacy of the bispecific T-cell engager in patients with high-risk, heavily pretreated multiple myeloma, including after...